HighField has received clearance for its IND application from the CDE of China's NMPA to commence the Phase I trial of HF50.

The Phase II Orchestra trial ended meeting none of its endpoints as the company announces plans to pivot from the drug in favour of others.

Sanofi and Teva Pharmaceuticals have reported that the Phase IIb RELIEVE UCCD study of the human IgG1-λ2 monoclonal antibody targeting TL1A, duvakitug, met its primary endpoints in patients with ...

The trial of the company’s metastatic pancreatic cancer treatment, elraglusib, similarly saw the one-year survival rate reach 43.6%.

Netherlands-based global health platform myTomorrows has added the ISRCTN platform to its platform’s clinical trial search functionality. The platform now includes clinical trial information from a ...

The company’s chronic thyroid eye disease treatment, veligrotug, was able to reduce eye bulge by 56% compared with placebo.

Bowel cancer, also known as colorectal cancer, is an aggressive cancer with a high incidence in developed countries.

The two-day event included talks on subjects ranging from how to best utilise AI to how to build a stable CRO.

Corcept Therapeutics has reported positive outcomes from its Phase III study of relacorilant, a treatment for endogenous hypercortisolism.

MindMed has dosed the first subject in a Phase III study of MM120 tablets for the treatment of generalised anxiety disorder.

A recent study carried out by researchers in Burkina Faso and the UK, and published in The Lancet Infectious Diseases, has shown that the first blood-stage malaria vaccine, RH5.1/Matrix-M, is safe, ...

Incyclix Bio has reported outcomes from the dose escalation part of the Phase I/II INX-315-01 trial of INX-315 for breast cancer treatment.